Teriparatide
Stimulates new bone growth to strengthen bones. Used when osteoporosis risk is high.
This peptide is an FDA-approved drug product that can be legally prescribed by licensed clinicians.
The basics
- Generic Name
- teriparatide (PTH 1-34 analog)
- Brand Names
- Forteo
- Regulatory Status
- Prescribed by Doctors
- Therapeutic Areas
- Musculoskeletal, Endocrine
- Prescribing Specialties
- Endocrinology, Rheumatology, Primary care
What it does
Teriparatide is an FDA-approved medication that your doctor can prescribe. Recombinant parathyroid hormone fragment (amino acids 1-34) that stimulates new bone formation by activating osteoblasts when given intermittently.
How it's taken
Daily subcutaneous injection
How people access it
Prescribed by endocrinologists or rheumatologists for osteoporosis. Filled at a specialty or retail pharmacy.
What doctors prescribe it for
- Osteoporosis in postmenopausal women at high risk for fracture
- Osteoporosis in men at high risk for fracture
- Glucocorticoid-induced osteoporosis
Clinicians may prescribe FDA-approved drugs for off-label uses based on their clinical judgment. Off-label indications have not undergone the same FDA review process as the labeled uses listed above.
How to know it's legit
You can independently verify the FDA-approval status of Teriparatide through these free, publicly available databases:
- DailyMed (dailymed.nlm.nih.gov) — Search for Forteo to find the current FDA-approved labeling, including indications, dosing, warnings, and contraindications.
- Drugs@FDA (accessdata.fda.gov/scripts/cder/daf/) — Search to find the original approval letter, review documents, and approval history.
- FDA Orange Book (orangebook.fda.gov) — Search for therapeutic equivalence evaluations and patent/exclusivity information.
Common Questions
Yes. Teriparatide (Forteo) is an FDA-approved drug product. It has undergone rigorous review of safety, efficacy, and manufacturing quality by the FDA. It can be legally prescribed by licensed clinicians for its approved indications.
Teriparatide is FDA-approved for: Osteoporosis in postmenopausal women at high risk for fracture; Osteoporosis in men at high risk for fracture; Glucocorticoid-induced osteoporosis. Off-label use may be considered by clinicians on a case-by-case basis, but only the labeled indications have been reviewed and approved by the FDA.
You can verify the approval status of Teriparatide through several official FDA resources: DailyMed (dailymed.nlm.nih.gov) for current labeling, Drugs@FDA (accessdata.fda.gov/scripts/cder/daf/) for approval history, and the FDA Orange Book for therapeutic equivalence information. These are free, publicly available databases.
Want to learn more?
Explore how Teriparatide compares to other options, or dive deeper into how FDA approval works.
Explore All Peptides